Trial Profile

A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen With Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy During Acute HIV-1

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teropavimab (Primary) ; Vesatolimod (Primary) ; Zinlirvimab (Primary) ; HIV vaccine
Indications HIV-1 infections
Focus Adverse reactions; Therapeutic Use

02 Jul 2025 Status changed from suspended to recruiting.
23 Apr 2025 Status changed from recruiting to suspended. Reason the study was stopped: Temporarily Closed (Paused) to Accrual
05 Feb 2025 Planned End Date changed from 29 Apr 2026 to 1 Aug 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com